APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

被引：30

作者：

Grossi, Federico V. ^{[1
]}

Bedwell, Pauline ^{[2
]}

Deschatelets, Pascal ^{[1
,3
]}

Edis, Lil

Francois, Cedric G. ^{[1
]}

Johnson, Patrick J. ^{[4
]}

Richardson, Helen J. ^{[5
]}

Tan, Lisa ^{[6
]}

Vega, Carolina A. ^{[1
]}

Lickliter, Jason ^{[7
]}

机构：

[1] Apellis Pharmaceut Inc, Crestwood, KY USA

[2] PB Clin Serv Ltd, Minster, England

[3] Apellis Australia Pty Ltd, Brisbane, Qld, Australia

[4] JPharma Solut GmbH, Zurich, Switzerland

[5] Paramstat Ltd, Sandwich, Kent, England

[6] Lisa Tan Pharma Consulting, Cambridge, England

[7] Nucleus Network Ltd, Melbourne, Vic, Australia

来源：

关键词：

D O I：

10.1182/blood.V128.22.1251.1251

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1251

引用

页数：4